🔗 Share this article

As the US undertakes unprecedented revisions to its vaccine guidelines, a particular individual appears somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus shots throughout the pandemic and has focused upon alleged fatalities after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Program

Agency leaders were set to announce sweeping revisions to the pediatric vaccination calendar in December, aligning the US with Denmark’s vaccine program, sources say – a major change that would place the US out of alignment with much of the world with no evidence for benefit. This reveal has been delayed until the coming year.

In place of Vinay Prasad, Dr. Høeg is scheduled to present at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to lead the office this calendar year.

A New Direction at the FDA

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine branches as Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon reevaluating long-standing vaccines at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric vaccine recommendations in the US so as to align more like Denmark's approach, a society with nationalized medicine and a number of inhabitants approximately the population of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – typically the domain of Prasad, director of the FDA’s CBER – as opposed to medication approval.

Concerns Over Expertise

Høeg has no obvious background in pharmaceutical research, approval processes or leadership, which has been standard for previous directors of the biologics center. She has served at the FDA as a key advisor to the agency head and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for running the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a major agency. She lacks background in pharmaceutical oversight.”

Former commissioners of CBER would “be deeply familiar with regulatory frameworks and the science of drug development”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that former directors who headed the center have had.”

This division has an enormous range of responsibilities at the agency, Woodcock pointed out.

“Everybody just zeroes in on the innovative therapies, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and other areas, and all of those need to be supervised,” she explained. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a significant leadership element to the role, which supervises over 5,000 employees. “It is a huge management job, if you do it right,” she concluded.

Official Statement and Contentious Initiatives

Regarding questions about Dr. Høeg's credentials and whether this selection represents more teamwork among agency officials on immunizations, a press secretary stated that the “inquiries stem from incorrect assumptions”.

“Her experience aligns with the functions of her job,” the representative explained, pointing to the time Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Høeg assumes responsibility for the commissioner’s controversial expedited review system, a disputed one-day drug-approval program that apparently troubled her preceding directors. “By what process are these medications being picked for this voucher program? Who makes the calls?” Howard said. “There is a lot of lack of transparency going on at the agency right now.”

In general, he remarked, “the Food and Drug Administration appears to be shifting towards more relaxed rules of most medications, except for immunizations.”

Established History on Immunizations

With immunizations, Høeg has a more established, if concerning, history, critics observe. She published a research paper using unverified volunteer-provided data to determine the incidence of heart inflammation following COVID-19 vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the new federal leadership encompassed revising rules for novel immunizations and ending “non-essential” immunizations, she stated post-election on a audio program. At the FDA, Høeg has according to sources floated the idea of excluding adolescent males from receiving COVID-19 vaccines.

“She’s an all-around dogmatist who commences with her beliefs and works backwards to retrofit the evidence in a very deceptive, untruthful fashion,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|